SAB Biotherapeutics Inc (SABS) Unusual Options Activity Today

Checking SABS unusual options activity helps you spot when traders are making outsized bets on SAB Biotherapeutics Inc before the broader market catches on. SAB Biotherapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor SABS unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching SABS unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking SABS unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and SABS unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors.

Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Catalysts rarely arrive without a footprint, and SABS unusual options activity is often where that footprint shows up first. Our scanner tracks SAB Biotherapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at SABS unusual options volume on the call side or chasing put sweeps, SAB Biotherapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.